Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab
Author:
Publisher
BMJ
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference7 articles.
1. Schulze-Koops H , Krueger K , Vallbracht I , et al . Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2021;80:e67. doi:10.1136/annrheumdis-2020-218075
2. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study;Loarce-Martos;Rheumatol Int,2020
3. Persistent COVID-19 pneumonia and failure to develop Anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma;Yasuda;Clin Lymphoma Myeloma Leuk,2020
4. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia;Lancman;J Hematol Oncol,2020
5. Hanson KE , Caliendo AM , Arias CA , et al . The infectious diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. Clin Infect Dis 2021.doi:10.1093/cid/ciab048
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Vaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients;ERJ Open Research;2023-08-03
2. COVID‐19 disease frequency, risk factors, and re‐infection rates in patients with autoimmune rheumatic disease receiving rituximab;International Journal of Rheumatic Diseases;2023-03-21
3. Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications;Journal of Clinical Immunology;2022-07-02
4. Low Positivity Rate of Anti–SARS-CoV-2 IgG in Unvaccinated Patients With Rheumatic Diseases Treated With Rituximab;JCR: Journal of Clinical Rheumatology;2022-06-12
5. Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review;Case Reports in Infectious Diseases;2022-02-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3